Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C

Journal of Viral Hepatitis

Volumn 9, Issue 5, 2002, Pages 334-339

  Layden, Thomas J ^a,e   Layden, Jennifer E ^a   Reddy, K Rajender ^b   Levy Drummer, Rachel S ^c   Poulakos, Jennifer ^d   Neumann, Avidan U ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c BAR ILAN UNIVERSITY   (Israel)

^d AMGEN INC   (United States)

^e 840 S Wood/Digestive and Liver Diseases   (United States)

Author keywords

Hepatitis C; IFN; Induction therapy; Mathematical modelling; Sustained viral response (SVR); Viral kinetics

Indexed keywords

CONSENSUS INTERFERON; VIRUS RNA;

ADULT; ARTICLE; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; KINETICS; LINEAR REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RNA ANALYSIS; VIRUS DETECTION;

ADULT; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; REMISSION INDUCTION; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0036378296     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00376.x     Document Type: Article

References (23)

1. Hoofnagle JH, Tralka TS. The National Institutes of Health Consensus Development Conference: Management of Hepatitis C. Hepatology 1997; 26(3): (Suppl 1): 785-825.
2. McHutchinson JG, Gordon SC, Schiff ER et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
3. Poynard T, Marcellin P, Lee SS et al. Interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Ther Group (IHIT). Lancet 1998; 352: 1426-1432.
4. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha. Hepatology 1997; 26: 226-231.
5. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha-therapy. Science 1998; 282: 103-107.
6. Fried MW, Shiffman M, Sterling RK et al. A multicenter, randomized trial of daily high-dose IFN-α2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95: 3225-3229.
7. Hadziyannis AS, Papaioannou C, Spanou F, Manesis EK, Hadziyannis SJ. Induction IFN therapy in naïve patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol 2001; 15: 551-557.
8. Carithers RL, Zeuzem S, Manns MP et al. Multicenter randomized controlled trial comparing high dose daily induction IFN plus ribavirin versus standard IFN α-2b plus ribavirin. Hepatology 2000; 32(4) (Part 2): 317A.
9. Van Vlierberghe H, Leroux-Roels G, Bourgeois N et al. Daily induction combination treatment with IFN α-2b or standard combination treatment in naïve chronic hepatitis C patients: a controlled multicenter randomized trial. Hepatology 2000; 32(4) (Part 2): 364A.
10. Peine CJ, Albrecht JK, Roel J et al. A comparison of standard and induction IFN therapy with and without initial ribavirin in treatment naïve patients with chronic Hepatitis C. Hepatology 2000; 32(4) (Part 2): 364A.
11. Bini E, Mannix R. High dose IFN α-2b in combination with ribavirin significantly improves sustained virologic response rates and health-related quality of life in veterans with chronic hepatitis C. Hepatology 2001; 34(4) (Part 2): 335A
12. Larson S, Rajvanshi P, Lee S, Polyak S, Gretch D, Carithers R. High dose induction leads to improved sustained viral clearance in HCV genotype 1 patients. Hepatology 2001; 34(4) (Part 2): 336A.
13. Karino Y, Toyota J, Sugawara M et al. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. AJG 1997; 301: 61-65.
14. Zeuzem S, Lee J, Franke A et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alpha. Hepatology 1998; 27: 1149-1154.
15. Orito E, Mizokami M, Suzuki K et al. Loss of serum HCV RNA at week 4 of interferon alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995; 46: 109-115.
16. Brouwer J, Hansen B, Niesters H, Schalm S. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT. J Hepatol 1999; 30: 192-198.
17. Gavier B, Martinez-Gonzalex M, Riezu-Boj J et al. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 1997; 113: 1647-1653.
18. Civiera M, Prieto J. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol 1999; 31: 237-243.
19. Izopet J, Payen J, Alric L et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 1998; 54: 86-91.
20. Lee W, Reddy R, Tong M et al. Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. Hepatology 1998; 28: 1411-1416.
21. Neumann AU, Layden TJ, Reddy R, Levi-Drummer R, Poulakos J. The 2nd phase slope of HCV decline is highly predictive of sustained virologic response following CIFN treatment for chronic hepatitis C and is determined by genotype but not dose. Hepatology 2000; 32(4) (Part 2): 356A.
22. Neumann AU, Dahari H, Conrad A, Pianko S, McHutchison JG. Early prediction and mechanism of the ribavirin/IFN-alpha dual therapy effect on chronic hepatitis C virus (HCV) infection. Hepatology 1999; 30(4) (Part 2): 320A.
23. Neumann AU, Reddy R, Levy-Drummer R et al. IFN pharmokinetics and host factor: effects on hepatitis C genotype 1 viral kinetics during treatment with CIFN. Hepatology 2001: 34(4) (Part 2): 428A.